More adverse events occurred in the augmented treatment group than in the standard group ( asparaginase-related hypersensitivity in 18 [ 67 % ] in the augmented group vs two [ 08 % ] in the standard group and asparaginase-related pancreatitis in eight [ 30 % ] vs one [ 04 % ] ; intravenous methotrexate-related mucositis in 11 [ 41 % ] vs three [ 11 % ] and methotrexate-related stomatitis in 48 [ 180 % ] vs 12 [ 45 % ] ) .